Our results suggest that the miR-203/survivin/Bmi-1 axis in LSCs could be a valuable therapeutic target, and further studies focused on this axis may facilitate development of novel therapeutic strategies and potential diagnostic and prognostic markers for AML treatment. The gene discussed is BIRC5; the disease is acute myeloid leukemia.